Pain Therapeutics Invites you to Join a Conference Call on Third Quarter 2018 Financial Results
The Company’s conference call can be accessed by dialing toll-free (877) 407-4018 (or 201 689-8471 for international callers). A replay will be available toll-free at (844) 512-2921, (or 412 317-6671 for international callers), using the conference ID code 13684539.
To listen to the Company’s webcast, please go to http://www.paintrials.com/ and click on “News”, then “Event & Presentations” to register. You may access http://www.paintrials.com/ at any time through
About the Company’s Neuroprotection Program
Our lead drug candidate, PTI-125, is a small molecule with a unique mechanism of action for treating Alzheimer’s disease (“AD”). We expect to initiate a Phase IIa study with PTI-125 in AD in Q4 2018.
The underlying science for PTI-125 is published in prestigious peer-reviewed journals, including
We are also developing a blood-based test, called PTI-125Dx, to detect whether a person has Alzheimer’s disease, possibly years before any symptoms appear. An early diagnosis of AD could optimize treatment options and empower physicians and patients to slow or halt the disease.
About Alzheimer's Disease
Alzheimer’s Disease (AD) is a progressive brain disorder that destroys memory and thinking skills. Eventually, a person with AD may be unable to carry out even the simplest tasks. There is a profound and timely need to develop new drugs for Alzheimer’s. Currently, there are no drug therapies to halt Alzheimer’s, much less reverse its course.
We develop proprietary drugs and diagnostics that offer significant improvements to patients and physicians. Our expertise consists of developing new products and guiding these through various regulatory and development pathways in preparation for their eventual commercialization. The
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").
For More Information Contact:
Chief Financial Officer
Source: Pain Therapeutics, Inc.